BCA
LGND icon

Benchmark Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Benchmark Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-33,342
Closed -$1.4M – 130
2014
Q1 		$1.4M Sell
33,342
-6,733
-17% -$281K 0.97% 34
2013
Q4 		$1.31M Buy
+40,075
New +$1.31M 0.91% 38
2013
Q3 		– Sell
-84,799
Closed -$1.98M – 135
2013
Q2 		$1.98M Buy
+84,799
New +$1.53M 1.53% 20

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Benchmark Capital Advisors's LGND Position: Q2 2014 in Review

Benchmark Capital Advisors sold out of Ligand Pharmaceuticals (LGND) in Q2 2014, closing a stake of 33,342 shares — an estimated $1.4M sold.

Benchmark Capital Advisors first reported a position in LGND in Q2 2013 and held it in 3 quarters. The position peaked at $1.98M in Q2 2013. 192 funds tracked by Wall St. Rank hold LGND as of Q2 2014.

  • Benchmark Capital Advisors reported no remaining Ligand Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Benchmark Capital Advisors sold 33,342 Ligand Pharmaceuticals shares in Q2 2014, an estimated $1.4M.
  • Benchmark Capital Advisors first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Benchmark Capital Advisors's Ligand Pharmaceuticals position peaked at $1.98M in Q2 2013.
  • 192 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2014.

Based on Benchmark Capital Advisors's 13F filing for Q2 2014, filed 6 Aug 2014.